

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**COMP/M.6033 - JOHNSON & JOHNSON / CRUCCELL**

**SECTION 1.2**

**Description of the concentration**

1. On 21 December 2010 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No. 139/2004. The envisaged transaction concerns a public bid leading to the acquisition of a maximum of 100% of the shares in Crucell N.V. ("Crucell") by Johnson & Johnson ("JNJ"). As a result of the concentration, JNJ will acquire sole control over Crucell.
  
2. The business activities of the undertakings concerned are:
  - JNJ: (1) consumer health and care products, including beauty, oral care, baby, over-the-counter medicines, nutritional, women's health, wellness and prevention products, (2) medical devices and diagnostics and (3) pharmaceutical products;
  
  - Crucell: the research, development, production and sale of biologic medicinal products (i.e. vaccines, proteins and antibodies) for the prevention or treatment of infectious diseases.

